middle.news
Invion Raises $1.3M to Fast-Track Cancer Trials with CEO’s Backing
8:06pm on Friday 30th of January, 2026 AEDT
•
Healthcare
Read Story
Invion Raises $1.3M to Fast-Track Cancer Trials with CEO’s Backing
8:06pm on Friday 30th of January, 2026 AEDT
Key Points
Convertible note raise of $1.3 million led by CEO Prof Thian Chew and major shareholder Ms XiaoYi Wu
Funds targeted at clinical trials for non-melanoma skin cancer and anogenital cancer
Convertible notes feature no interest, a conversion floor of 9 cents, and a three-year expiry
Near-term milestones include ethics approvals and clinical readouts
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invion (ASX:IVX)
OPEN ARTICLE